CardioVascular and Interventional Radiology, ISSN 0174-1551, 12/2015, Volume 38, Issue 6, pp. 1523 - 1531
The purpose of this study was to evaluate feasibility, safety, tolerance, and efficacy of drug-eluting beads loaded with irinotecan (DEBIRI) in combination...
Neoplasm | Hepatic | Medicine & Public Health | Liver | Interventional Oncology | Tumor | Nuclear Medicine | Imaging / Radiology | Cardiology | Ultrasound | Chemoembolization | CARDIAC & CARDIOVASCULAR SYSTEMS | MONOTHERAPY | PLUS IRINOTECAN | RESECTION | LONG-TERM SURVIVAL | CONSENSUS | OXALIPLATIN | FLUOROURACIL | CANCER | CHEMOTHERAPY | Y-90 RADIOEMBOLIZATION | RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING | Capecitabine - administration & dosage | Prospective Studies | Humans | Middle Aged | Male | Treatment Outcome | Antimetabolites, Antineoplastic - administration & dosage | Drug Delivery Systems | Feasibility Studies | Chemoembolization, Therapeutic - methods | Disease-Free Survival | Antineoplastic Agents, Phytogenic - administration & dosage | Colorectal Neoplasms - therapy | Camptothecin - administration & dosage | Colorectal Neoplasms - secondary | Female | Liver Neoplasms - pathology | Aged | Camptothecin - analogs & derivatives | Chemotherapy | Liver diseases | Capecitabine | Analysis | Metastasis | Stent (Surgery) | Cancer
Neoplasm | Hepatic | Medicine & Public Health | Liver | Interventional Oncology | Tumor | Nuclear Medicine | Imaging / Radiology | Cardiology | Ultrasound | Chemoembolization | CARDIAC & CARDIOVASCULAR SYSTEMS | MONOTHERAPY | PLUS IRINOTECAN | RESECTION | LONG-TERM SURVIVAL | CONSENSUS | OXALIPLATIN | FLUOROURACIL | CANCER | CHEMOTHERAPY | Y-90 RADIOEMBOLIZATION | RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING | Capecitabine - administration & dosage | Prospective Studies | Humans | Middle Aged | Male | Treatment Outcome | Antimetabolites, Antineoplastic - administration & dosage | Drug Delivery Systems | Feasibility Studies | Chemoembolization, Therapeutic - methods | Disease-Free Survival | Antineoplastic Agents, Phytogenic - administration & dosage | Colorectal Neoplasms - therapy | Camptothecin - administration & dosage | Colorectal Neoplasms - secondary | Female | Liver Neoplasms - pathology | Aged | Camptothecin - analogs & derivatives | Chemotherapy | Liver diseases | Capecitabine | Analysis | Metastasis | Stent (Surgery) | Cancer
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 03/2019, Volume 37, Issue 8_suppl, pp. 44 - 44
44 Background: The emerging role of immunotherapy (IT) in cancer treatments has increased the research about tumor microenvironment (TME), tumor infiltrating...
Journal Article
1983, BAR international series, ISBN 0860542041, Volume 160, 292
Book
Journal of Cellular Physiology, ISSN 0021-9541, 06/2017, Volume 232, Issue 6, pp. 1571 - 1578
Bevacizumab in combination with taxanes in HER2‐negative metastatic breast cancer (MBC) patients has shown improved progression‐free survival (PFS), despite...
PHASE-III TRIAL | PHYSIOLOGY | EFFICACY | SAFETY | LETROZOLE | OPEN-LABEL | LOCALLY RECURRENT | COMBINATION | PLUS BEVACIZUMAB | CHEMOTHERAPY | PROGRESSION | CELL BIOLOGY | Multivariate Analysis | Bevacizumab - therapeutic use | Humans | Middle Aged | Proportional Hazards Models | Receptor, ErbB-2 - metabolism | Treatment Outcome | Breast Neoplasms - drug therapy | Paclitaxel - therapeutic use | Disease-Free Survival | Neoplasm Metastasis | Breast Neoplasms - pathology | Aged, 80 and over | Adult | Female | Aged | Maintenance Chemotherapy | Retrospective Studies | Breast cancer | Metastasis | Angiogenesis inhibitors | Analysis | Paclitaxel | Therapy | Toxicity | Maintenance | Multivariate analysis | Patients | Survival | ErbB-2 protein | Bevacizumab | Metastases | Training | Breast | Taxanes | Cancer | Index Medicus | Original
PHASE-III TRIAL | PHYSIOLOGY | EFFICACY | SAFETY | LETROZOLE | OPEN-LABEL | LOCALLY RECURRENT | COMBINATION | PLUS BEVACIZUMAB | CHEMOTHERAPY | PROGRESSION | CELL BIOLOGY | Multivariate Analysis | Bevacizumab - therapeutic use | Humans | Middle Aged | Proportional Hazards Models | Receptor, ErbB-2 - metabolism | Treatment Outcome | Breast Neoplasms - drug therapy | Paclitaxel - therapeutic use | Disease-Free Survival | Neoplasm Metastasis | Breast Neoplasms - pathology | Aged, 80 and over | Adult | Female | Aged | Maintenance Chemotherapy | Retrospective Studies | Breast cancer | Metastasis | Angiogenesis inhibitors | Analysis | Paclitaxel | Therapy | Toxicity | Maintenance | Multivariate analysis | Patients | Survival | ErbB-2 protein | Bevacizumab | Metastases | Training | Breast | Taxanes | Cancer | Index Medicus | Original
Journal Article
5.
Full Text
Gemcitabine versus FOLFIRINOX in patients with advanced hENT1+ve pancreatic adenocarcinoma
Journal of Clinical Oncology, ISSN 0732-183X, 05/2015, Volume 33, Issue 15_suppl, pp. e15295 - e15295
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 02/2019, Volume 37, Issue 4_suppl, pp. 669 - 669
669 Background: Nowadays the optimal treatment for mCRC beyond second line is still questioned. During last years, regorafenib and TAS-102 showed to improve...
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 05/2019, Volume 37, Issue 15_suppl, pp. 3558 - 3558
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 05/2019, Volume 37, Issue 15_suppl, pp. e15039 - e15039
Journal Article
10.
Full Text
c-Myc expression as a key-marker in the colorectal cancer resistance to EGFR inhibitors
Journal of Clinical Oncology, ISSN 0732-183X, 05/2016, Volume 34, Issue 15_suppl, pp. e15034 - e15034
Journal Article
Journal of Phycology, ISSN 0022-3646, 10/2016, Volume 52, Issue 5, pp. 774 - 792
Hypnea has an intricate nomenclatural history due to a wide pantropical distribution and considerable morphological variation. Recent molecular studies have...
synonymy | Hypnea flexicaulis | Cystocloniaceae | single‐marker delimitation methods | Hypnea tenuis | taxonomy | systematics | Hypnea aspera | single-marker delimitation methods | Species Specificity | Algal Proteins - genetics | Brazil | Rhodophyta - classification | Phylogeny | Rhodophyta - genetics | DNA Barcoding, Taxonomic | Sequence Analysis, DNA | Rhodophyta - anatomy & histology
synonymy | Hypnea flexicaulis | Cystocloniaceae | single‐marker delimitation methods | Hypnea tenuis | taxonomy | systematics | Hypnea aspera | single-marker delimitation methods | Species Specificity | Algal Proteins - genetics | Brazil | Rhodophyta - classification | Phylogeny | Rhodophyta - genetics | DNA Barcoding, Taxonomic | Sequence Analysis, DNA | Rhodophyta - anatomy & histology
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 02/2019, Volume 37, Issue 4_suppl, pp. 671 - 671
671 Background: Hepatic resection is the gold standard treatment for pts with liver-limited mCRC with 5- and 10-yrs survival rates reaching up to 60% and 20%....
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 02/2017, Volume 35, Issue 4_suppl, pp. 629 - 629
629 Background: Presently few options are available for pts with mCRC who failed standard treatments and prognosis remains grim. MGMT promoter methylation is a...
Journal Article
Modern Pathology, ISSN 0893-3952, 07/2015, Volume 28, Issue 7, pp. 954 - 964
Germline PDGFRA mutations cause multiple heterogeneous gastrointestinal mesenchymal tumors. In its familial form this disease, which was formerly termed...
TRACT | INFLAMMATORY FIBROID POLYPS | GIST | KIT | MUTATIONS | PATHOLOGY | DEVON FAMILY | GASTROINTESTINAL STROMAL TUMORS | EXPRESSION | MULTIPLE | Gastrointestinal Neoplasms - genetics | Colonic Polyps - pathology | Humans | Middle Aged | Male | Syndrome | Gastrointestinal Neoplasms - pathology | Colonic Polyps - genetics | Pedigree | Receptor, Platelet-Derived Growth Factor alpha - genetics | Gastrointestinal Stromal Tumors - pathology | Adult | Female | Aged | Mutation | Gastrointestinal Stromal Tumors - genetics
TRACT | INFLAMMATORY FIBROID POLYPS | GIST | KIT | MUTATIONS | PATHOLOGY | DEVON FAMILY | GASTROINTESTINAL STROMAL TUMORS | EXPRESSION | MULTIPLE | Gastrointestinal Neoplasms - genetics | Colonic Polyps - pathology | Humans | Middle Aged | Male | Syndrome | Gastrointestinal Neoplasms - pathology | Colonic Polyps - genetics | Pedigree | Receptor, Platelet-Derived Growth Factor alpha - genetics | Gastrointestinal Stromal Tumors - pathology | Adult | Female | Aged | Mutation | Gastrointestinal Stromal Tumors - genetics
Journal Article
Journal of the American College of Cardiology, ISSN 0735-1097, 10/2019, Volume 74, Issue 13, pp. B465 - B465
Journal Article
Journal of the American College of Cardiology, ISSN 0735-1097, 10/2019, Volume 74, Issue 13, pp. B464 - B464
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 01/2015, Volume 33, Issue 3_suppl, pp. 724 - 724
724 Background: Treatment options for metastatic colorectal cancer (mCRC) patients refractory to chemotherapy are limited and clinical outcome is poor. In mCRC...
Journal Article
Future Oncology, ISSN 1479-6694, 06/2013, Volume 9, Issue 6, pp. 771 - 776
cancer | hospice | supportive care | palliative treatment | CANCER PAIN | END | MANAGEMENT | ONCOLOGY | MORPHINE | PERSPECTIVES
Journal Article
Hepatology, ISSN 0270-9139, 07/2017, Volume 66, Issue 1, pp. 235 - 251
Hepatocellular carcinoma (HCC) represents the fifth‐most common form of cancer worldwide and carries a high mortality rate attributed to lack of effective...
HEPATOCELLULAR-CARCINOMA | OBESITY | HIGH-FAT-DIET | GENE | METABOLISM | PHOSPHORYLATION | FARNESOID-X RECEPTOR | MECHANISMS | GUT MICROBIOTA | BETA-CATENIN | GASTROENTEROLOGY & HEPATOLOGY | Genomic Instability | Liver Neoplasms - genetics | Oxidative Stress | Risk Assessment | Mice, Inbred C57BL | Risk Factors | Repressor Proteins - genetics | Male | Mice, Transgenic | Random Allocation | Tripartite Motif-Containing Protein 28 | Carcinogenesis - pathology | Phenotype | Animals | Aging - genetics | Epigenomics - methods | Carcinoma, Hepatocellular - genetics | Diet, High-Fat | Carcinoma, Hepatocellular - pathology | Female | Liver Neoplasms - pathology | Mice | Disease Models, Animal | Obesity | Chromatin | Transcription | Androgen receptors | Mortality | Hepatocellular carcinoma | Dimorphism | Metabolism | Males | Carcinogenesis | High fat diet | Liver cancer | Sex hormones | Androgens | Rodents | Aging | Sexual dimorphism | Digestive tract | Bile | Tumors | Index Medicus | Original
HEPATOCELLULAR-CARCINOMA | OBESITY | HIGH-FAT-DIET | GENE | METABOLISM | PHOSPHORYLATION | FARNESOID-X RECEPTOR | MECHANISMS | GUT MICROBIOTA | BETA-CATENIN | GASTROENTEROLOGY & HEPATOLOGY | Genomic Instability | Liver Neoplasms - genetics | Oxidative Stress | Risk Assessment | Mice, Inbred C57BL | Risk Factors | Repressor Proteins - genetics | Male | Mice, Transgenic | Random Allocation | Tripartite Motif-Containing Protein 28 | Carcinogenesis - pathology | Phenotype | Animals | Aging - genetics | Epigenomics - methods | Carcinoma, Hepatocellular - genetics | Diet, High-Fat | Carcinoma, Hepatocellular - pathology | Female | Liver Neoplasms - pathology | Mice | Disease Models, Animal | Obesity | Chromatin | Transcription | Androgen receptors | Mortality | Hepatocellular carcinoma | Dimorphism | Metabolism | Males | Carcinogenesis | High fat diet | Liver cancer | Sex hormones | Androgens | Rodents | Aging | Sexual dimorphism | Digestive tract | Bile | Tumors | Index Medicus | Original
Journal Article
Cancer Immunology, Immunotherapy, ISSN 0340-7004, 7/2019, Volume 68, Issue 7, pp. 1179 - 1185
No standard treatment has been defined for metastatic uveal melanoma (mUM). Although clinical trials testing Nivolumab/Pembrolizumab for cutaneous melanoma did...
Pembrolizumab | Liver metastases | Immunology | Medicine & Public Health | First line | Immunotherapy | Uveal melanoma | Oncology | Cancer Research | CELLS | ONCOLOGY | PD-L1 EXPRESSION | LIVER | EXPERIENCE | IMMUNOLOGY | IPILIMUMAB | Care and treatment | Analysis | Liver | Melanoma | Metastasis | Drug therapy | Cancer | PD-1 protein | Toxicity | PD-L1 protein | Clinical trials | Diagnosis | Survival | Patients | Disease control | Metastases | Original
Pembrolizumab | Liver metastases | Immunology | Medicine & Public Health | First line | Immunotherapy | Uveal melanoma | Oncology | Cancer Research | CELLS | ONCOLOGY | PD-L1 EXPRESSION | LIVER | EXPERIENCE | IMMUNOLOGY | IPILIMUMAB | Care and treatment | Analysis | Liver | Melanoma | Metastasis | Drug therapy | Cancer | PD-1 protein | Toxicity | PD-L1 protein | Clinical trials | Diagnosis | Survival | Patients | Disease control | Metastases | Original
Journal Article
No results were found for your search.
Cannot display more than 1000 results, please narrow the terms of your search.